5 results about "Chloroquinocin" patented technology

The invention belongs to the field of chemical analysis and testing, and particularly relates to a quinoline derivative coumarin fluorescent probe targeting tobramycin and a preparation method of the quinoline derivative coumarin fluorescent probe. The preparation method comprises the following steps: dissolving N1-(7-chloroquinoline-4-yl) ethane-1, 2-diamine and 7-(diethylamino) coumarin-3-formic acid in dichloromethane, adding condensing agents of 1-hydroxybenzotriazole (HOBT), 1-ethyl-(3-dimethylamino aldehyde) carbodiimide hydrochloride (EDCI) and triethylamine, carrying out a stirring reaction at room temperature, carrying out separation and purification on an obtained crude product through silica gel column chromatography, and carrying out recrystallization to obtain the 7-(diethylamino) coumarin-3-carboxylic acid-N-(7-chloroquinoline-4-yl) coumarin-3-carboxylic acid-N-(7-chloroquinoline-4-yl) coumarin-3-carboxylic acid-N-(7-chloroquinoline-4-yl) coumarin-3-carboxylic acid. The coumarin fluorescent probe DL containing the quinoline derivatives is obtained. The prepared coumarin fluorescent probe forms a complex under the participation of Cu < 2 + >, and tobramycin can be specifically and rapidly detected in deionized water.

This invention belongs to the pharmaceutical field, specifically relating to the synthesis of pharmaceutical intermediate compounds. Specifically, it relates to a method for preparing montelukast sodium using (E)-1-[3-(2-(7-chloroquinoline-2-yl)vinyl)phenyl]prop-2-en-1-ol and 2-(2-iodophenyl)prop-2-yl acetate as raw materials. This method not only has good impurity removal effects but also high product yield and purity. Furthermore, it does not require stringent synthesis conditions, making it suitable for large-scale industrial production.

The invention provides a synthesis method of 4, 7-dichloroquinoline, and relates to the technical field of compound preparation. Comprising the following steps: synthesizing 7-chloro-4-hydroxyquinoline-2-carboxylic acid by a one-pot method, and then carrying out decarboxylation and chlorination on the 7-chloro-4-hydroxyquinoline-2-carboxylic acid to obtain the 4, 7-dichloroquinoline. Wherein the step of synthesizing the 7-chloro-4-hydroxyquinoline-2-carboxylic acid by the one-pot method comprises the following steps: condensing m-chloroaniline and diethyl oxaloacetate to obtain a compound shown as a formula 3, directly adding condensation reaction liquid into an organic solvent, and heating and cyclizing to obtain 7-chloro-4-hydroxyquinoline-2-carboxylic acid ethyl ester; after the cyclization reaction is completed, sodium hydroxide is added for hydrolysis, and 7-chloro-4-hydroxyquinoline-2-carboxylic acid is obtained. The method has the advantages of simple operation, high productivity, safety, environmental protection, easily available raw materials, and suitableness for industrial production.

This invention discloses a continuous flow synthesis method for olutanib, belonging to the field of pharmaceutical synthesis technology. The method involves mixing a solution of 2-cyano-5-fluoropyridine with an acidic solution of hydrogen peroxide and reacting the mixture in a first continuous flow reactor at 70-90°C to obtain intermediate 3; mixing a solution of 3 with an acid anhydride and reacting the mixture in a second continuous flow reactor at 90-100°C to obtain intermediate 4; pumping a solution of 4 and a methylating agent into a third continuous flow packed bed reactor and reacting the solution at 20-25°C to obtain intermediate 5; and then reacting intermediate 5 with (… S A solution of 3-(1-aminoethyl)-6-chloroquinoline-2(1H)-one was pumped into a fourth continuous flow packed bed reactor and reacted at 90-95°C. The resulting product was then purified to obtain olutanib. The total residence time of this method is only 118 minutes, eliminating the need for column chromatography purification. The process is continuous, safe, and controllable, with high production efficiency and ease of scale-up.

The application belongs to the field of enzyme catalysis, and particularly relates to optimization of an improved carbonyl reductase sequence, construction of an engineering bacterium and application of the engineering bacterium in catalysis of a montelukast sodium intermediate. The application provides a carbonyl reductase and an engineering bacterium, wherein the bacterium takes (E)-2-(3-(3-(2-(7-chloro-2-quinolinyl)vinyl)phenyl)-3-oxopropyl)benzoic acid methyl ester as a starting substrate, realizes efficient synthesis of a product S-(E)-2-(3-(3-(2-(7-chloro-2-quinolinyl)vinyl)phenyl)-3-hydroxypropyl)benzoic acid methyl ester in the presence of the carbonyl reductase, and solves problems of low substrate concentration, high production cost and long conversion time in a traditional method, wherein a substrate conversion rate is greater than or equal to 99.6%, a molar yield reaches 95%, and a product chiral purity reaches 100%.